Linked Life Data

8449864

Source:http://linkedlifedata.com/resource/pubmed/id/8449864

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1993-4-12
pubmed:abstractText
Recent studies suggest that the administration of intensive post-remission therapy, which includes high-dose cytarabine, results in a longer period of disease-free survival when compared with lower dose treatment. In view of these improved results, it is uncertain currently whether younger patients with acute myeloid leukemia (AML) in first remission should be offered such intensive chemotherapy or either allogeneic or autologous bone marrow transplantation. Currently ongoing clinical trials, laboratory-based prognostic factor analysis, and attempts at better understanding the pathophysiology of acute leukemia may provide more precise guidelines for choosing the best treatment among these alternatives for any given individual with AML in first remission.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0889-8588
pubmed:author
pubmed:issnType
Print
pubmed:volume
7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
47-64
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed:year
1993
pubmed:articleTitle
Treatment of the newly diagnosed adult with de novo acute myeloid leukemia.
pubmed:affiliation
Department of Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.
pubmed:publicationType
Journal Article, Review